Phoenix Biotech Acquisition Corp. (PBAX) to Combine with CERo Therapeutics in $112M Deal

Phoenix Biotech (NASDAQ:PBAX) has entered into a definitive agreement to combine with pre-cliinical drug developer CERo at an enterprise value of $112 million. San Francisco-based CERo is developing a line of potential cancer treatments and expects to file its first investigational new drug (IND) application in 2024. The combined company is expected to trade on
Read More